AIGH Capital Management LLC Sells 34,118 Shares of Castle Biosciences, Inc. $CSTL

AIGH Capital Management LLC cut its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 5.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 590,601 shares of the company’s stock after selling 34,118 shares during the quarter. Castle Biosciences makes up approximately 2.0% of AIGH Capital Management LLC’s portfolio, making the stock its 11th biggest position. AIGH Capital Management LLC’s holdings in Castle Biosciences were worth $14,499,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CSTL. Federated Hermes Inc. acquired a new stake in shares of Castle Biosciences in the fourth quarter valued at about $26,000. Kemnay Advisory Services Inc. bought a new stake in Castle Biosciences in the fourth quarter valued at approximately $35,000. Mirae Asset Global Investments Co. Ltd. increased its position in Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Castle Biosciences by 140.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock valued at $68,000 after purchasing an additional 1,022 shares during the period. Finally, CWM LLC raised its holdings in Castle Biosciences by 20.5% during the 4th quarter. CWM LLC now owns 2,302 shares of the company’s stock worth $90,000 after purchasing an additional 391 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 3,622 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $24.29, for a total value of $87,978.38. Following the transaction, the insider directly owned 12,368 shares of the company’s stock, valued at approximately $300,418.72. This trade represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,586 shares of Castle Biosciences stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $24.42, for a total transaction of $209,670.12. Following the transaction, the chief operating officer owned 21,874 shares of the company’s stock, valued at $534,163.08. This represents a 28.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 49,361 shares of company stock valued at $1,119,278. 6.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CSTL. Roth Capital started coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target on the stock. BTIG Research decreased their price objective on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings downgraded shares of Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Robert W. Baird dropped their target price on shares of Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Wall Street Zen cut shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.43.

Castle Biosciences Price Performance

Shares of CSTL opened at $23.64 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.53 and a current ratio of 6.75. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $44.28. The business’s 50 day moving average price is $21.51 and its two-hundred day moving average price is $28.24. The firm has a market cap of $717.00 million, a PE ratio of -53.73 and a beta of 1.00.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. The firm had revenue of $84.23 million during the quarter, compared to the consensus estimate of $79.23 million. On average, equities analysts anticipate that Castle Biosciences, Inc. will post -1.56 EPS for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.